

Evkeeza[®]
evinacumab for injection

ONTARIO

^{Pr}EVKEEZA[®] (evinacumab for injection) is covered* for patients with HoFH on a case-by-case basis through the Ontario [Exceptional Access Program \(EAP\)](#).

*Coverage is not guaranteed and is subject to the patient meeting Ontario's EAP criteria.

What Is EVKEEZA and How Does It Work?

EVKEEZA is the first and only ANGPTL3 inhibitor indicated as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 6 months and older with homozygous familial hypercholesterolemia (HoFH).

The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

Please consult the Product Monograph at <https://www.ultragenyx.ca/evkeezaproductmonograph> for important information relating to warnings and precautions, adverse reactions, breastfeeding, drug interactions, and dosing information.

The Product Monograph is also available by calling us at 1-833-388-5872.

For more information on applying for EVKEEZA[®] coverage, we can arrange an appointment at your convenience, or you can go to the [UltraCare website](#). You can also find the [UltraCare Enrolment Form](#) on the UltraCare website.